Budesonide-dependent modulation of expression of macrophage migration inhibitory factor in a polyposis model: Evidence for differential regulation in surface and glandular epithelia

Annals of Otology, Rhinology and Laryngology

Volumn 113, Issue 7, 2004, Pages 544-551

  Delbrouck, Carine ^a,b   Gabius, Hans Joachim ^a,d   Kiss, Robert ^a,c   Vandenhoven, Guy ^a,e   Hassid, Sergio ^a,b  

^a Erasmus University Hospital ^*

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITY OF MUNICH   (Germany)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Budesonide; Glucocorticoid; Inflammation; Macrophage migration inhibitory factor; Nasal polyp; Polyposis

Indexed keywords

BUDESONIDE; CORTICOSTEROID; MACROPHAGE MIGRATION INHIBITION FACTOR;

ARTICLE; CANCER SURGERY; CELL TYPE; COMPUTER ANALYSIS; CORTICOSTEROID METABOLISM; CYTOKINE RELEASE; DOSE RESPONSE; DRUG MECHANISM; GLANDULAR EPITHELIUM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; MACROPHAGE MIGRATION INHIBITION; MICROSCOPIC ANATOMY; NOSE MUCOSA; NOSE POLYP; POLYPOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE DIAGNOSIS; REGULATORY MECHANISM; SURFACE EPITHELIUM;

EID: 3142579769     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940411300706     Document Type: Article

References (40)

1. Stoop AE, van der Heijden HA, Biewenga J, van der Baan S. Eosinophils in nasal polyps and nasal mucosa: an immunohistochemical study. J Allergy Clin Immunol 1993;91:616-22.
2. Bernstein JM, Gorfien J, Noble B. Role of allergy in nasal polyposis: a review. Otolaryngol Head Neck Surg 1995;113:724-32.
3. Mygind N. Advances in the medical treatment of nasal polyps. Allergy 1999;54(suppl 53):12-6.
4. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966;153:80-2.
5. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 1966;56:72-7.
6. Parant M, Le Contel C, Parant F, Chedid L. Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha. Lymphokine Cytokine Res 1991;10:265-71.
7. Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC, David JR. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A 1989;86:7522-6.
8. Calandra T, Bucala R. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol 1997;17:77-88.
9. Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000;20:751-62.
10. Honma N, Koseki H, Akasaka T, et al. Deficiency of the macrophage migration inhibitory factor gene has no significant effect on endotoxaemia. Immunology 2000;100:84-90.
11. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 1998;160:5693-6.
12. Shimizu T, Ohkawara A, Nishihira J, Sakamoto W. Identification of macrophage migration inhibitory factor (MIF) in human skin and its immunohistochemical localization. FEBS Lett 1996;381:199-202.
13. Donnelly SC, Haslett C, Reid PT, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997;3:320-3.
14. Leech M, Metz C, Hall P, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999;42:1601-8.
15. Kitaichi N, Kotake S, Sasamoto Y, et al. Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophthalmol Vis Sci 1999;40:247-50.
16. Murakami H, Akbar SM, Matsui H, Onji M. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest 2001;31:337-43.
17. de Jong YP, Abadia-Molina AC, Satoskar AR, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001;2:1061-6.
18. Huang XR, Chun Hui CW, Chen YX, et al. Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology 2001;121:619-30.
19. Ohwatari R, Fukuda S, Iwabuchi K, Inuyama Y, Onoe K, Nishihira J. Serum level of macrophage migration inhibitory factor as a useful parameter of clinical course in patients with Wegener's granulomatosis and relapsing polychondritis. Ann Otol Rhinol Laryngol 2001;110:1035-40.
20. Onodera S, Tanji H, Suzuki K, et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 1999;11:163-7.
21. Korsgren M, Kallstrom L, Uller L, et al. Role of macrophage migration inhibitory factor (MIF) in allergic and endotoxin-induced airway inflammation in mice. Mediators Inflamm 2000;9:15-23.
22. Shimizu T, Abe R, Ohkawara A, Nishihira J. Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitis. J Allergy Clin Immunol 1999;104:659-64.
23. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68-71.
24. Donnelly SC, Bucala R. Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today 1997;3:502-7.
25. Zeng FY, Weiser WY, Kratzin H, Stahl B, Karas M, Gabius HJ. The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor. Arch Biochem Biophys 1993;303:74-80.
26. Kayser K, Bovin NV, Korchagina EY, Zeilinger C, Zeng FY, Gabius HJ. Correlation of expression of binding sites for synthetic blood group A-, B- and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma. Eur J Cancer 1994;30A:653-7.
27. Nagy N, Decaestecker C, Dong X, et al. Characterization of ligands for galectins, natural galactoside-binding immunoglobulin G subfractions and sarcolectin and also of the expression of calcyclin in thyroid lesions. Histol Histopathol 2000;15:503-13.
28. Camby I, Nagy N, Lopes MB, et al. Supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas are characterized by a differential expression of S100 proteins. Brain Pathol 1999;9:1-19.
29. Hassid S, Decaestecker C, Hermans C, et al. Algorithm analysis of lectin glycohistochemistry and Feulgen cytometry for a new classification of nasal polyposis. Ann Otol Rhinol Laryngol 1997;106:1043-51.
30. Camby I, Salmon I, Danguy A, et al. Influence of gastrin on human astrocytic tumor cell proliferation. J Natl Cancer Inst 1996;88:594-600.
31. Janssen T, Petein M, van Velthoven R, et al. Coregulatory effects of epidermal growth factor, dihydrotestosterone and prolactin on benign human prostatic hyperplasia tissue culture proliferation. Prostate 1997;30:47-52.
32. Philippart P, Harper L, Chaboteaux C, et al. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin Cancer Res 2000;6:1557-62.
33. Gabius HJ, Darro F, Remmelink M, et al. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest 2001;19:114-26.
34. Rosengren E, Bucala R, Aman P, et al. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 1996;2:143-9.
35. McGlone JJ, Lumpkin EA, Norman RL. Adrenocorticotropin stimulates natural killer cell activity. Endocrinology 1991;129:1653-8.
36. Vacchio S, Ashwell JD. Thymus-derived glucocorticoids regulate antigen-specific positive selection. J Exp Med 1997;185:2033-8.
37. Leech M, Metz C, Bucala R, Morand EF. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43:827-33.
38. Delbrouck C, Doyen I, Belot N, et al. Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration. Lab Invest 2002;82:147-58.
39. a epitopes and respective binding sites in human nasal polyps maintained under ex vivo tissue culture conditions. Ann Otol Rhinol Laryngol 2002;111:1097-107.
40. Gabius HJ. Probing the cons and pros of lectin-induced immunomodulation: case studies for the mistletoe lectin and galectin-1. Biochimie 2001;83:659-66.